Association of Plasma Homocysteine Level and Arterial Stiffness in Subjects with Type 2 Diabetes Mellitus.
- Author:
Jenie Yoonoo HWANG
1
;
Chang Hee JUNG
;
Min Jung LEE
;
Yu Mi KANG
;
Woo Je LEE
;
Joong Yeol PARK
Author Information
- Publication Type:Original Article
- Keywords: Type 2 diabetes mellitus; Homocysteine; Arterial stiffness
- MeSH: C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Hemoglobins; Homocysteine; Humans; Linear Models; Plasma; Pulse Wave Analysis; Retrospective Studies; Risk Factors; Vascular Stiffness
- From:Journal of Lipid and Atherosclerosis 2013;2(1):27-35
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: Plasma homocysteine (Hcy) is considered to be a marker of endothelial dysfunction and a predictor of cardiovascular disease (CVD). Arterial stiffness measured by brachial-ankle pulse wave velocity (baPWV) is not only a marker of vascular damage but a significant predictor of CVD. Previous studies about the effect of high plasma Hcy levels on arterial stiffness have yielded inconsistent results. We therefore assessed the association between Hcy and baPWV in a relatively large number of subjects with type 2 diabetes mellitus (DM). METHODS: We retrospectively assessed plasma Hcy concentration and arterial stiffness in 1,477 Korean type 2 diabetic patients. Participants were also evaluated for plasma glucose, hemoglobin A1c (HbA1c), duration of DM, microvascular complications, lipid profile, and high sensitivity C-reactive protein (hsCRP). Arterial stiffness was measured noninvasively by baPWV. RESULTS: Correlation analysis indicated a significant positive association between serum Hcy levels and baPWV (r=0.245, p<0.001). In a multiple linear regression analysis, the association between serum Hcy levels and baPWV was independent of traditional cardiovascular risk factors (standardized beta=3.8, p=0.01). CONCLUSION: The results support the hypothesis that plasma Hcy levels are associated with arterial stiffness in patients with type 2 DM. Prospective studies are warranted to determine whether lowering serum Hcy level could reduce arterial stiffness and cardiovascular morbidity in type 2 DM.
